Editors' declarations of interest
Professor J M Rhodes, Editor
Professor Rhodes is, or has been, a member of advisory boards for
Atlantic, Pharmacosmos, Procter and Gamble, Vifor and Falk, has
received speaking honoraria from Abbott, Falk, Ferring, Glaxo Smith
Kline, Merck, Procter and Gamble, Schering Plough, Shire and Wyeth,
and with the University of Liverpool and Provexis UK, holds a patent
for use of a soluble fibre preparation as maintenance therapy for
Crohn’s disease plus a patent for its use in antibiotic-associated diar-
rhoea. He also holds a patent with the University of Liverpool and
others in relation to the use of modified heparins in cancer therapy.
Professor C W Howden, Editor
Professor Howden is a consultant for Ironwood, Pfizer Consumer
Health, Otsuka, SynteractHCR, and US World Meds. He has received
speaking honoraria from Horizon. He is a member of the Clinical
Events Committee overseeing a clinical trial for EndoStim. He is cur-
rently an expert witness for Allergan and Mylan in patent litigation
matters and has been retained as an expert witness on behalf of
Takeda. He has previously acted as an expert witness on behalf of
Apotex, Roxane Laboratories and Teva.
Professor P C Hayes, Associate Editor
Professor Hayes recently acted in an advisory capacity, has been
paid to speak at meetings or had travel support with AbbVie, BMS,
Eisai Ltd, Falk, Ferring, Gilead, Gore, Janssen, Lundbeck, MSD, Nor-
gine, Novartis, ONO Pharmaceuticals, Pfizer and Roche.
Professor A C Ford, Associate Editor
Professor Ford has received grant/research support from Almirall,
GE Healthcare, Tillotts Pharma, and Falk and acted as a consultant/
speaker for Almirall, GE Healthcare, Ipsen Pharma SPA, Mayoly-
Spindler, MSD, Norgine and Shire Pharmaceuticals.
Professor G M Dusheiko, Associate Editor
Professor Dusheiko currently serves on advisory boards for AbbVie,
Gilead Sciences, Janssen, Merck and Shionogi. He has received speak-
ing honoraria from Gilead Sciences, AbbVie, and Merck in the past 2
years. He has acted as an advisor to the National Institute of Clinical
Excellence. He has served on several safety monitoring boards includ-
ing Regulus, Shionogi, Transgene and Enanta in the past two years.
Professor A L Hart, Associate Editor
Professor Hart has served as consultant, advisory board member or
speaker for AbbVie, Allergan, Atlantic, Bristol-Myers Squibb, Cell-
trion, Falk, Ferring, Hospira, Janssen, MSD, Napp Pharmaceuticals,
Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Glo-
bal Steering Committee for Genentech.
Professor P R Gibson, Associate Editor
Professor Gibson has served as consultant or advisory board member
for Allergan, Celgene, Danone, Ferring, Janssen, MSD, Pfizer and
Takeda. His institution has received speaking honoraria from Danone,
Ferring, Janssen and Nestle Health Science. He has received research
grants for investigator-driven studies from AbbVie, Danone, MSD and
A2 Milk Company. His Department financially benefits from the sales
of a digital application and booklets on the low FODMAP diet. He has
published an educational/recipe book on diet.
Professor S A Harrison, Associate Editor
Professor Harrison has received remuneration for acting in an advisory
capacity to Aegerion, Alexion, Allergan, Axcella, CiVi Biopharma, Sec-
ond Genome, Metacrine, Novartis, CLDF, Echosens, Genfit, Novo-
Nordisk, Gilead, Intercept, NGM Biopharma, Madrigal, Novartis, Cirius,
Perspectum, HistoIndex, Capulus, Cymabay, Prometheus and Pfizer.
He has received speaker honoraria from Abbvie and Alexion.
Professor G L-H Wong, Associate Editor
Professor Wong has served as an advisory committee member for
Gilead Sciences. She has served as a speaker for Abbott, AbbVie,
Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, and Roche.
Dr N A Kennedy, Associate Editor
Dr Kennedy has served as a speaker and/or advisory board member
for Allergan, Falk, Pharmacosmos and Takeda. He has had support to
attend meetings from AbbVie, Falk, Janssen and Norgine. His depart-
ment has received research funding from AbbVie, Celgene, Celtrion,
MSD, Napp, Pfizer and Takeda.
Dr M D Burkitt, Reviews Editor
Dr Burkitt has received support to attend meetings from Allergan
Professor R E Pounder, Founding Editor 1987–2017; Emeritus Editor
and Advisor 2018-present.
None to declare.
If an Editor has a potential conflict of interest with the contents of a
manuscript, usually that manuscript will be transferred to another
Editor. Occasionally, because of the specialist nature of some manu-
scripts and limited experience of the other Editors, the manuscript
may remain under the supervision of the original specialist Editor,
who will confer with other Editors before making a decision.
14 May 2018
© 2018 John Wiley & Sons Ltd wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther. 2018;48:4.